Women with hypoparathyroidism persisting beyond one year after surgery to remove the thyroid have more calcium deposits in their breast arteries, which may indicate a higher risk for cardiovascular disease, according to a study from Turkey. However, because no cardiovascular data were available, these calcifications should be viewed “as…
News
Children are more likely than adults to develop hypoparathyroidism after total thyroidectomy, probably because this surgery to remove the thyroid glands can disrupt their blood supply even when the nearby parathyroid glands are not accidentally removed, a study suggested. However, “permanent hypoparathyroidism was uncommon,” researchers wrote in the study,…
Canada’s Drug Agency (CDA-AMC) is urging that Yorvipath (palopegteriparatide) — an injection therapy approved in the country earlier this year — be reimbursed for eligible adults with hard-to-treat chronic hypoparathyroidism. The agency, responsible for aligning drug policy across Canada, has recommended that patients prescribed Yorvipath be eligible for…
The use of teriparatide, a lab-made version of the parathyroid hormone — low levels of which lead to hypoparathyroidism — should not replace supplement therapy in children with the rare condition, but may benefit young patients who don’t respond well to standard care. That’s the key takeaway from…
People with chronic hypoparathyroidism who are treated by endocrinologists — doctors who specialize in hormone-related diseases — are more likely to achieve recommended blood levels of calcium and vitamin D than those not receiving specialist care, a real-world study found. The researchers noted that these effects were observed despite…
Levels of parathyroid hormone (PTH) on the day after thyroidectomy – a surgery to remove the thyroid gland – may accurately help rule out permanent hypoparathyroidism, a study in Turkey suggests. Almost 4% of nearly 500 people who underwent surgical thyroid removal developed permanent hypoparathyroidism. Having a second surgery…
Daily treatment with Yorvipath (palopegteriparatide) leads to rapid and sustained improvement in kidney function among adults with hypoparathyroidism, according to newly published data from the PaTHway trial, whose earlier results were used to back the drug’s widespread approvals. Gains in kidney health for these patients were seen regardless…
Treatment for at least three years with Yorvipath (palopegteriparatide), an approved daily hormone replacement therapy used to help manage blood calcium levels in adults with hypoparathyroidism, led to sustained improvements in calcium control for patients taking part in a clinical trial. New results from the Phase 3 study,…
Men with chronic hypoparathyroidism may be more likely to develop chronic kidney disease (CKD), while women with the disorder may face higher risks of bone fractures, anxiety, and cognitive problems, according to a review study. Researchers also found that menopause, disease duration, and the underlying cause of hypoparathyroidism…
Children with hypoparathyroidism that is not a consequence of surgery may face a significant risk of kidney complications later in life, particularly calcium deposits and reduced function, but careful control of calcium and phosphate levels during treatment may help lower that risk, a long-term study in China found. The…
Recent Posts
- I’m finally learning that pushing past my limits has lasting effects
- Like Rocky, I’m facing my own ‘steps’ with the ‘Eye of the Tiger’
- After nearly 3 decades with hypopara, I’m finally applying for SSDI
- Long-term hypoparathyroidism tied to calcium deposits in breasts
- Entering the Jewish new year with hope, despite hypopara challenges